HOOKIPA Pharma Inc.’s shares have soared after stating it amended and restated a collaboration and license agreement with Gilead Sciences to develop immunotherapies against HIV.
Senseonics has finally received approval from the U.S. Food and Drug Administration for its Eversense E3 Continuous Glucose Monitoring System (CGM) System.
The EMA’s safety committee has announced that they are reviewing reports of menstrual disorders after people received COVID-19 vaccinations from Pfizer-BioNTech and Moderna.
Ardelyx has reported in a regulatory filing that the FDA sent an Appeal Denied Letter for its drug tenapanor, a therapeutic intended for chronic kidney disease.
REGENXBIO presented results from its ongoing Phase I/II trial of RGX-111, an investigational one-time gene therapy for people with Mucopolysaccharidosis Type I (MPS I).
enGene announced positive results from its LEGEND Phase I/II clinical trial for treating high-grade NMIBC in patients with carcinoma in situ that are unresponsive to BCG treatment.
New York-based Ovid Therapeutics and Healx have entered a strategic partnership to investigate the compound gaboxadol to treat Fragile X Syndrome (FXS).
Business with customers in the pharma and biotech sector was a key revenue driver, said Thermo Fisher CEO Marc Casper, adding that this business grew by 25% over the year.
Specialty vaccine company Valneva and Pfizer have reported positive Phase II data from their clinical trial evaluating a Lyme Disease vaccine candidate.
The collaboration will focus on expanding targeted protein degradation therapies through the discovery of previously unrecognized molecular glues or monovalent degraders.
CRISPR Therapeutics and ViaCyte dosed their first patient in Phase I clinical trial of a novel gene-edited cell replacement therapy to treat Type 1 Diabetes.
Finally, Pfizer has submitted the request to FDA to grant emergency use status to their vaccine for children. Here’s everything you should know about the vaccine.
